Evidence map›Paper›PMID 40498693›Full record

ArticlePloS one2025

Bayesian optimization and machine learning for vaccine formulation development.

Lillian Li, Sung-In Back, Jian Ma, Yawen Guo, Thomas Galeandro-Diamant, Didier Clénet

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lillian LiVaccine CMC Development & Supply, Sanofi, Toronto, Ontario, Canada.ORCID https://orcid.org/0009-0009-1625-0059
Sung-In BackVaccine CMC Development & Supply, Sanofi, Toronto, Ontario, Canada.
Jian MaVaccine CMC Development & Supply, Sanofi, Toronto, Ontario, Canada.
Yawen GuoVaccine CMC Development & Supply, Sanofi, Marcy-L' Etoile, France.
Thomas Galeandro-DiamantChemAI Ltd. West Hill House, Allerton Hill, Chapel Allerton, Leeds, United Kingdom.ORCID https://orcid.org/0000-0002-1068-013X
Didier ClénetVaccine CMC Development & Supply, Sanofi, Marcy-L' Etoile, France.ORCID https://orcid.org/0000-0002-8395-9430

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developing vaccines with a better stability is an area of improvement to meet the global health needs of preventing infectious diseases. With the advancement of data science and artificial intelligence, innovative approaches have emerged. This manuscript highlights the applications of machine learning through two cases in which Bayesian optimization was used to develop viral vaccine formulations. The two case studies monitored the critical quality attributes of virus A in liquid form by infectious titer loss and virus B in freeze-dried form by glass transition temperature. Stepwise analysis and model optimization demonstrated progressive improvements of model quality and prediction accuracy. The cross-validation matrices of the models' predictions showed high R² and low root mean square errors, indicating their reliability. The prediction accuracy of models was further validated by using test datasets. Model analysis using prediction error plot, Shapeley Additive exPlanations, permutation importance, etc. can provide additional insights into relations between model and experimental design, the influence of features of interest, and non-linear responses. Overall, Bayesian optimization is a useful complementary tool in formulation development that can help scientists make effective data-driven decisions.

Indexed as

Machine LearningVaccine DevelopmentBayes TheoremHumansVaccinesVaccines

Identifiers

PMID40498693
PMCPMC12157168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.